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ABSTRACT 
 
Introduction: The aim of this study was to analyze patterns of persistent versus recurrent or new 
PET lesions in a selected patient cohort with PSA persistence following salvage lymph node 
dissection (SLND) and pre/post procedure prostate-specific membrane antigen ligand positron 
emission tomography (PSMA-PET). 
Material and Methods: 16 patients were included in this multicenter study. Inclusion criteria were: a) 
PSMA-PET performed for biochemical recurrence before SLND (pre-SLND PET) and b) repeat 
PSMA-PET performed for persistently elevated PSA level (≥0.1 ng/mL) ≥6 weeks after SLND (post-
SLND PET). Image analysis was performed by three independent nuclear medicine physicians 
applying the molecular imaging TNM system PROMISE. Lesions were confirmed by histopathology, 
presence on correlative CT/MRI/bone scan or PSA response after focal therapy. 
Results: post-SLND PET identified PCa-lesions in 88% (14/16) of patients with PSA persistence after 
SLND. Median PSA was 1.2 ng/mL (IQR, 0.6-2.8 ng/mL). Disease was confined to the pelvis in 56% 
of patients (9/16) and most of these men had common iliac (6/16, 38%) and internal iliac lymph node 
metastases (6/16, 38%). Extrapelvic disease was detected in 31% of patients (5/16). In pre- and post-
SLND PET comparison, 10/16 had at least one lesion already detected at baseline (63% PET 
persistence); 4/16 had new lesions only (25% PET recurrence); 2 had no disease on post-SLND PET. 
All validated regions (11 regions in 9 patients) were true positive. 9/14 (64%) patients underwent 
repeat local therapies after SLND (7/14 radiotherapy, 2/14 surgery). 
Conclusions: SLND of pelvic nodal metastases was often not complete according to PSMA-PET. 
About two thirds of patients had PET positive nodal disease after SLND already seen on pre-
SLND PSMA-PET. Notably, about one quarter of patients had new lesions, not detected by pre-
surgical PSMA-PET. 
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INTRODUCTION 
In cases of biochemical recurrence after radical prostatectomy (RP) it is important to determine 
whether the recurrence has developed at local or distant sites. Therefore, current guidelines 
recommend prostate-specific membrane antigen ligand positron emission tomography (PSMA-
PET)-imaging if the outcome will affect treatment planning (1). Promising efficacy of metastases-
directed therapy such as salvage lymph node dissection (SLND) or salvage radiotherapy (S-RT) has 
been reported in several studies (2,3), but evidence on the long-term oncological impact is missing. In 
patients with longer PSA doubling times, lower RP specimen pathological ISUP grades and disease 
recurrence confined to lymph nodes, metastases-directed therapy aims at decreased risk of distant 
progression, later onset of ADT and potential improvement of cancer-specific survival. PSMA-PET 
provides localization of biochemically recurrent prostate cancer (PCa) with unprecedented accuracy 
even at low PSA levels (4–7). Resection of suspicious nodes is feasible, however more than half of 
patients demonstrate persistently elevated PSA following SLND (8). Accurate staging is helpful to 
localize the source of PSA for subsequent management decisions, including surveillance, repeat 
localized salvage or systemic therapy. Disease locations individually guide local re-treatment to 
balance efficacy and potential toxicity (8). Conventional imaging does not localize relevant lesions 
in this clinical setting, especially at low PSA levels. PSMA-PET is a promising staging tool 
sensitive enough to uncover disease locations before and after salvage lymph node 
dissection. We hypothesize that PSMA-PET localizes residual and new PCa lesions in patients with 
PSA persistence following SLND with high accuracy. We therefore selected patients with pre/post 
procedure PSMA-PET to better understand disease patterns of unsuccessful salvage lymph 
node resection. 
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MATERIAL AND METHODS 
Patient Population 
Between June 2013 and April 2018, datasets from 7013 patients with PSMA-PET for PCa were 
retrospectively reviewed at 6 high-volume nuclear medicine centers and 16 patients with PSA 
persistence after SLND were enrolled (Fig. 1). Inclusion criteria were: a) PSMA-PET performed for 
biochemical recurrence of PCa before SLND (pre-SLND PET); b) repeat PSMA-PET performed for 
persistently elevated PSA level (≥0.1 ng/mL) ≥6 weeks after SLND (post-SLND PET). Anonymized 
data were centrally collected at the Department of Nuclear Medicine of the University Duisburg-Essen, 
Germany. This retrospective analysis was approved by the local ethics committee (reference number 
18-8136-BO), which waived requirement to obtain informed consent for inclusion. 
 
Image Acquisition 
68Ga-PSMA-11 (Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]) was used as the PSMA ligand. 
The median injected activity was 154 MBq (IQR 100-172 MBq). The median uptake time was 64 
minutes (IQR 56-77). Intravenous contrast was given before 26/32 (81%) PET/CT scans. PET imaging 
protocols were in accordance with the Joint SNMMI/EANM procedure guideline for PSMA-PET 
imaging (9). 
 
Image Interpretation 
Anonymized imaging datasets were evaluated independently by three experienced nuclear 
medicine physicians with at least two years of experience in PSMA-PET imaging following recent 
recommendations (9,10) and unaware of clinical history. Readers were trained based on 30 PSMA-
PET cases ranging from unremarkable to extensive disease and including typical pitfalls before 
analyzing images (11). Based on the molecular imaging TNM system PROMISE, the following regions 
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(subregions) were systematically rated as positive versus negative for PCa (12,13): prostate bed (T), 
pelvic nodes (N) (internal iliac, obturator, external iliac, mesorectal, presacral, common iliac), 
extrapelvic nodes (M1a) (retroperitoneal, mesenteric, inguinal, above diaphragm), bone (M1b), and 
visceral organs (M1c). In case of discordance, consensus (PET positive versus negative) was 
determined by 2 versus 1 majority vote among the three readers. 
 
Lesion Validation and Management 
Local investigators reviewed patient files for correlative and follow-up information acquired 
during routine clinical practice. Post-SLND PET-positive findings were confirmed by histopathology, 
presence of lesions on correlative CT/MRI/bone scan or PSA response >50% after focal therapy 
acquired during clinical routine. PET-positive findings were validated as true or false-positive on a 
region basis. 
 
Statistical Analysis 
For continuous data median and interquartile range (IQR) were reported, while categorical 
variables were described using frequencies. PSMA-PET detection rate for the localization of residual 
PCa post-SLND was determined on a patient basis stratified by PSA at the time of PET and PSA nadir 
after SLND. Association between PSMA-PET results, presence of local/distant lesions and PSA at the 
time of PET, PSA nadir, PSA doubling time (PSA-DT) or PSA velocity (PSA-V) was evaluated with 
non-parametric Mann-Whitney U tests in view of their asymmetric distribution. Furthermore, individual 
patient data are given. Overall agreement among three readers was evaluated using Fleiss’s kappa 
coefficient (κ). All analyses were performed using Stata software package, version 15 (StataCorp. 
2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). 
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RESULTS 
Patient characteristics are given in Table 1. The median PSA nadir after SLND was 0.4 ng/mL 
(IQR, 0.3-2.5 ng/mL) and the median PSA value at the time of PET post-SLND was 1.2 ng/mL (IQR, 
0.6-2.8 ng/mL). Individual patient characteristics and PET findings are listed in Table 2. Regarding 
PSA persistence, disease was localized post-SLND in 14/16 patients resulting in an overall detection 
rate of 88%. PSA at the time of PET, PSA nadir, PSA-DT or PSA-V were not significantly associated 
with post-SLND PET result (positive or negative) (Fig. 2). In the patient-based analysis, disease 
confined to the pelvis was detected in 56% of patients (9/16), with predominant pelvic nodal disease 
(9/16, 56%) and one local recurrence (1/16, 6%). Most frequently affected pelvic nodal regions were 
common iliac (6/16, 38%) and internal iliac (6/16, 38%). Distant disease was detected in 31% of 
patients (5/16). Extra-pelvic lymph nodes were detected in 4/16 patients (25%) whereas bone lesions 
in 1/16 (6%). There was a statistically significant association between higher PSA (p=0.047) or shorter 
PSA-DT (p=0.018) at the time of PET and presence of distant lesions. Longer PSA-DT was 
significantly associated with presence of local lesions only (p=0.02). PET positive pelvic nodes 
presented with intense PSMA uptake (median SUVmax 15; IQR 9-21), however most were not enlarged 
by CT criteria (median short diameter 0.8 cm; IQR 0.5-0.9). 
 
Pre- and Post-Surgery PET Comparison 
PSMA-PET was performed before SLND with a median time of 1 months (IQR, 1–2 months). 
The median time between SLND and PET post-SLND was 4 months (IQR, 2-6 months). Findings on 
PSMA-PET before SLND are listed in Supplemental Table 1. All lesions noted on pre-SLND PET were 
reported for surgery planning. Median number of lymph nodes removed at SLND was 17 (IQR, 10-20). 
Overall, pre-SLND PET detected 24 pelvic lymph node metastases whereas SLND resulted in 88 
histopathology positive nodes (226 nodes were removed in total). 
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After SLND, all men had PSA persistence (selection criteria for the current analysis). PET post-
SLND in these 16 patients demonstrated the following: 10 (63%) had at least one lesion already 
detected pre-SLND (PET persistence or mixed) whereas 4 (25%) had new lesions post-SLND only 
(PET recurrence) (Fig. 3). Most frequently affected nodal regions with PET persistence were internal 
iliac (5/10), obturator (3/10) and external iliac (3/10 N1 regions). Lesions recurred most often in 
common iliac (5/10) regions. 2/16 (13%) patients had no disease on PET post-SLND. 
Patient 8 presented mild focal uptake in the fifth left rib (SUVmax 3) before SLND. PET was read 
equivocal in absence of sclerosis on CT. PET post-SLND demonstrated intense focal uptake highly 
suggesting the presence of unifocal bone metastasis (SUVmax 14). Patient examples for persistent and 
recurrent metastases are given in Supplemental Figs. 1 and 2. 
 
Inter-Reader Agreement, Lesion Validation and Management 
Overall interpretation among three readers had fair agreement for the local prostate bed 
(Fleiss’ κ 0.33) and substantial to almost-perfect agreement for pelvic nodes (κ 0.69) and distant 
metastases (κ 0.68). 
Lesion validation was available in 9/16 patients (56%) and 11/11 validated regions were true 
positive: 5 with histology, 4 with imaging follow-up and 2 with PSA response >50% after S-RT (Table 
3). 
Management after PSMA-PET was recorded in 14/16 patients (88%). 9/14 (64%) patients had 
repeat local therapies: patients 1, 3, 10, 11, 13, 14 and 16 received S-RT ± ADT, patient 5 had repeat 
SLND. Patient 9 underwent salvage surgery confirming local PCa relapse with bladder invasion as 
well as a nodal metastasis. Patients 7 and 15 were started on ADT. Patient 2, 6 and 8 had 
surveillance. 
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DISCUSSION 
Patients undergoing SLND often experience PSA persistence or early relapse (8). As 
management of SLND failure is beyond guideline recommendations and often individually tailored, 
accurate staging of persistent disease is of high importance for subsequent management decisions. 
Treatment options include surveillance, systemic therapy or repeat salvage attempts for localized 
disease. 
Previously, PSMA-PET demonstrated superior accuracy for the localization of recurrent PCa at 
low PSA values (4,14). Furthermore, PSMA-PET localized persistent PCa after RP (15). In a SLND 
scenario, staging patients is crucial before proceeding with surgery. However, disease location 
and etiology of PSA failure has not been analyzed systematically yet. PSMA-PET provides high 
accuracy needed to map persistent and/or new lesions after unsuccessful SLND, even for sub 
centimeter lymph node metastases. 
In this study, repeat PSMA-PET was assessed in 16 patients to characterize patterns of 
persistent versus recurrent disease locations for unsuccessful SLND defined as PSA 
persistence (PSA  0.1 ng/mL) after surgery. 
This is the first study systematically comparing PSMA-PET before and after SLND for 
PSA persistence. In our highly selected cohort, repeat PSMA-PET localized disease in nearly all 
patients with biochemical failure after PET-informed salvage surgery. By comparing both pre-SLND 
and post-SLND PET we demonstrate that lesions were already noted on PET in about two 
thirds of patients before salvage-surgery (persistence). PET persistence was most often noted 
for the internal iliac and obturator regions with more difficult surgical access. The median size 
of PET-positive pelvic lymph nodes was 0.8 cm, thus, below CT/MRI size thresholds for metastatic 
disease (16,17). Pre-SLND PET findings were known to the surgeon and most of the PET-
by E-Library Insel on December 22, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
 
11 
 
positive regions were surgically explored during SLND indicating need for improved PET-
guidance for the standard resection templates. 
As demonstrated previously, PSMA-PET outside the prostate bed was highly reproducible 
and predictive for prostate cancer location (4,15). However, pre- and post-salvage surgery PSMA-
PET underestimated the total number of diseased nodes pre-SLND (17). Also, in about one-quarter 
of the patients, the PSMA-PET after SLND showed lesions which were not visible before SLND, 
rated as PET recurrence. PSA persistence indicates that lesions may have been present before 
surgery, but were not picked up due to sub maximal sensitivity of PSMA-PET. Deficiencies for 
the detection of small metastases have been characterized previously (17). Despite 
underestimation on a single lesion level, identification of diseased regions informs targeted therapy, 
including radiotherapy and repeat surgery, especially in a PSMA radio-guided setting (18). Focal 
therapy guided by PSMA-PET may lead to effective reduction in serum PSA levels (4). 
In our study, about two thirds of patients underwent repeat local therapy after SLND-failure. 
The addition of adjuvant radiotherapy might be beneficial with regards to improved local recurrence-
free survival (19). In this setting, patients might benefit from accurate PSMA-PET staging (20,21), 
however prospective randomized evidence is needed to assess oncologic outcomes.  
Furthermore, patients demonstrated short PSA-DT highlighting that patient selection for 
salvage interventions should not only be based on imaging but also consider PSA kinetics and 
pathological grades. 
Limitations of the present study are its retrospective design and the small cohort size of a 
highly selected patient group. Bias is introduced by selection of intra-individual pre and post 
SLND PSMA-PET pairs, which are typically not available in the standard SLND setting. Patient 
characteristics and increased imaging indicate high risk, which may have led to an 
overestimation of detection rates. Findings may not be applicable to a general cohort of 
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patients with SLND and PSA persistence. Moreover, surgical technique and eligibility criteria 
for SLND where not standardized among the enrolling centers. Findings might thus be not 
representative of the clinical salvage lymph node dissection scenario. 
 
CONCLUSION 
Comparison of pre- and post-procedure PSMA-PET revealed disease patterns in 
patients with biochemical persistence after salvage lymph node dissection: PSMA-PET 
identified locations of persistent disease in about two thirds of patients. Post-SLND PET further 
detected new or potentially growing metastases. About two thirds of patients underwent repeat local 
therapies after unsuccessful SLND, indicating potential value of accurate PSMA-PET staging for PSA 
persistence.  
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KEY POINTS 
QUESTION: Where is persistent or recurrent prostate cancer located in patients with 
unsuccessful salvage lymph node dissection? 
PERTINENT FINDINGS: This is a retrospective multicenter cohort study assessing pre- and post-
procedure PSMA-PET to localize prostate cancer in patients with PSA persistence following salvage 
lymph node dissection. PSMA PET/CT localizes residual disease in nearly all patients, most often in 
internal iliac and obturator regions. About one quarter of patients had new lesions, not detected by 
pre-surgical PSMA-PET. 
IMPLICATIONS FOR PATIENT CARE: PSMA-PET localized prostate cancer both before and after 
unsuccessful salvage lymph node dissection. Lesion persistence was most often noted for 
regions with difficult surgical access. 
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FIGURES 
 
Figure 1. Consort diagram for patient selection. 
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Figure 2. PSMA-PET detection Rate on a Patient Basis stratified by PSA at time of PET (A) and 
PSA nadir after SLND (B). 
 
  
by E-Library Insel on December 22, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
 
18 
 
Figure 3. PSMA-PET findings in the pre- and post-SLND PET comparison (n=16 patients) 
shown separately for (A) pelvic lymph nodes (N1) and (B) prostate bed (Tr), distant nodes 
(M1a) and bone metastases (M1b). 
 
Figure 3A 
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Figure 3B 
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TABLES 
 
Table 1. Patient characteristics (n=16). 
 Median IQR 
Age (years) 66 59–75 
PSA initial (ng/mL) 6.6 5.9–88.1 
PSA nadir after SLND (ng/mL) 0.4 0.3–2.5 
PSA at the time of PET (ng/mL) 1.2 0.6–2.8 
PSA-DT (months) 1.8 0-7.2 
PSA-V (ng/mL/years) 0.7 0-2.2 
∆ date pre-SLND PET - date SLND (months) 1.0 1-2 
∆ date SLND - date post-SLND PET (months) 3.5 2-6 
 Frequency % 
≥T3a 12/16 75 
N1 6/13 46 
ISUP Grade Group ≥4 11/16 69 
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Table 2. Patient details. Stage is given in accordance with PROMISE(12). 
Notes: RP, radical prostatectomy; S-RT, salvage-radiotherapy; SLND, salvage-lymph node dissection; EBRT, external beam radiation 
therapy; ADT, androgen deprivation therapy; Retrop, retroperitoneal; n/a, not available. 
 
Pati
ent 
Age 
(y) 
PSA at 
PET 
(ng/mL) 
ISUP 
Grade 
Group 
pTNM R 
Previous 
Treatments  
Positive on Pre-SLND PET 
Positive on SLND 
(histopathology) 
Positive on Post-SLND 
PET 
Pre- to post-PET 
diagnosis 
1 53 0.4 4 pT3b pN1 R0 RP T0N1(IIR)M0 IR T0N1(IIR)M0 Persistence 
2 68 0.4 2 pT2c pN0 R0 RP T0N1(OL)M0 OL T0N0M0 No disease 
3 65 0.5 5 pT3a pN1 R0 RP T0N1(OL,IIL)M0 PS/MR T0N1(OL,IIL)M0 Persistence 
4 63 0.8 5 pT3b n/a RP T0N1(IIL)M0 IIL,CIL T0N1(CIL,EIL)M0 New lesion/Recurrence 
5 67 1.0 3 pT2c pN0 R0 RP T0N1(OL,IIL)M0 IIL T0N1(CIL,OL,IIL)M0 Persistence 
6 75 1.1 2 pT2c pN0 R0 RP; S-RT T0N1(EIL)M0 EIL T0N0M0 No disease 
7 82 1.1 4 pT3b pN0 R1 RP; S-RT TrN1(EIR,EIL,OL)M0 negative T0N1(CIR,EIR,EIL)M0 Persistence 
8 55 1.3 5 pT3b pN1 R0 RP T0N0M1b(uni) negative T0N0M1b(uni) Persistence 
9 58 1.8 5 pT3b pN1 n/a RP T0N0M1a(Retrop) EIL,CIL TrN1(CIL)M0 New lesion/Recurrence 
10 63 2.0 5 pT3b pN1 R0 RP; ADT T0N1(CIL,EIL,IIL)M0 CIL,EIL,IIL T0N0M1a(Retrop) New lesion/Recurrence 
11 75 2.1 5 pT3b pN0 R1 RP T0N1(EIL,OL,IIR)M1a(INR) IIR 
T0N1(EIL,OL,IIR,PS/MR)
M1a(Retrop,INR) 
Persistence 
12 69 3.5 3 pT3a R1 RP; S-RT T0N0M1a(Retrop) n/a T0N0M1a(Retrop) Persistence 
13 83 3.6 4 pT3a pN0 n/a RP T0N0M0 PS/MR T0N1(IIR)M0 New lesion/Recurrence 
14 49 4.2 5 pT3b pN1 R1 
RP, S-RT; 
ADT 
T0N1(CIL,EIR,IIR,PS/MR)M1a(Retro
p) 
CIL,IIR,Retrop 
T0N1(CIR,IIR,PS/MR)M1a
(Retrop) 
Persistence 
15 74 12.0 4 pT3b R0 RP TrN1(CIR,EIR,PS/MR)M1a(Retrop) EIR T0N1(CIR,PS/MR)M0 Persistence 
16 60 0.5 3 pT2a pN0 R1 RP T0N1M0 negative T0N1M0 Persistence 
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Table 3. Lesion validation. 
 
 
 
 
 
 
 
Patient Validated region(s) Type of validation 
Validation 
result 
1 N1 PSA response after S-RT True positive 
5 N1 Surgery True positive 
8 M1b Imaging follow-up True positive 
9 Tr, N1 Surgery True positive 
11 N1, M1a Surgery, Imaging follow-up True positive 
13 N1 PSA response after S-RT True positive 
14 N1, M1a Surgery, Imaging follow-up True positive 
15 N1 Surgery True positive 
16 N1 Imaging follow-up True positive 
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Supplemental Material 
 
 
Supplemental Figure 1. Persistence of one internal iliac lymph node metastasis. 
53 year-old man initially treated with radical prostatectomy and lymph node dissection for high risk 
PCa (ISUP grade group 4, pT3b pN1 R0) underwent 68Ga-PSMA-11 PET/CT for disease restaging in 
October 2015 (PSA=0.36 ng/mL). Maximum-intensity-projection (a), axial PET/CT (b) and axial CT (e) 
demonstrated focal uptake in one right internal iliac node (arrows; 14x8 mm; SUVmax=4.5). With known 
PET-information, the patient was treated three weeks later with salvage lymph node dissection using a 
standard template (bilateral EI, II, CI resection). Histopathology confirmed adenocarcinoma in 1/12 
right internal iliac nodes. Six weeks after the intervention PSA was 0.18 ng/mL and the patient 
underwent repeat 68Ga-PSMA-11 PET/CT confirming now more intense uptake in a growing right 
internal iliac node positive on pre-PET (c-d; arrows; 20x9 mm; SUVmax=5.7; PET persistence). 
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Supplemental Figure 2. Recurrence of two obturator lymph node metastases. 
83 year-old man initially treated with radical prostatectomy and lymph node dissection for high risk 
PCa (ISUP grade group 4, pT3a pN0 R0) underwent 68Ga-PSMA-11 PET/CT for disease restaging in 
December 2015 with PSA=4.8 ng/mL. Maximum-intensity-projection (a) and axial PET/CT (b and e) 
demonstrate the absence of focal uptake within pelvis. With known information of PET and previous 
surgical fields, the patient was treated in January 2016 with more extended salvage lymph node 
dissection. Ten lymph nodes were removed from the following regions: right presacral, right 
obturatory, right iliac and paracaval; 1/10 resulted positive for PCa metastasis in the presacral region. 
Six weeks after the intervention PSA was 3.0 ng/mL and the patient underwent repeat 68Ga-PSMA-11 
PET/CT showing the appearance of two small right internal iliac nodes (8x6 mm) with PSMA uptake. 
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Supplemental Table 1. Pre-SLND PET findings. 
 
 
 
 
 
 
 
Characteristic Overall population (n=16; 100%) 
ADT  
No 14 (88) 
Yes 2 (12) 
Positive PSMA-PET 15 (94) 
Pelvic nodes only (N1) 9 (60) 
Retroperitoneal nodes only (M1a) 2 (13) 
Both (N1 M1a) 3 (20) 
Other 1 (7) 
N/M disease extent  
1 (unifocal) 6 (38) 
2-3 (oligo) 4 (25) 
≥4 (multiple/disseminated) 5 (31) 
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